204 related articles for article (PubMed ID: 34611919)
1. Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
Sirab N; Drubay D; Maillé P; Popova T; Ngo C; Gentien D; Moktefi A; Soyeux-Porte P; Pelletier R; Reyes C; Henry E; Pouessel D; Vordos D; Lebret T; de Reyniès A; Paoletti X; Radvanyi F; Allory Y
J Pathol; 2022 Jan; 256(1):108-118. PubMed ID: 34611919
[TBL] [Abstract][Full Text] [Related]
2. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis.
Schallenberg S; Dragomir MP; Anders P; Ebner B; Volz Y; Eismann L; Rodler S; Casuscelli J; Buchner A; Klauschen F; Stief C; Horst D; Schulz GB
Eur Urol Focus; 2023 Sep; 9(5):788-798. PubMed ID: 37076398
[TBL] [Abstract][Full Text] [Related]
4. Progression-associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis.
Fontugne J; Wong J; Cabel L; Neyret-Kahn H; Karboul N; Maillé P; Rapinat A; Gentien D; Nicolas A; Baulande S; Sibony M; Bernard-Pierrot I; Radvanyi F; Allory Y
J Pathol; 2023 Apr; 259(4):455-467. PubMed ID: 36695554
[TBL] [Abstract][Full Text] [Related]
5. Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
Koll FJ; Döring C; Olah C; Szarvas T; Köllermann J; Hoeh B; Chun FK; Reis H; Wild PJ
BMC Cancer; 2023 Jun; 23(1):504. PubMed ID: 37270477
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts.
Sjödahl G; Jackson CL; Bartlett JM; Siemens DR; Berman DM
J Pathol; 2019 Apr; 247(5):563-573. PubMed ID: 30604486
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.
Benítez R; Yu K; Sirota M; Malats N; Pineda S
Front Immunol; 2023; 14():986598. PubMed ID: 36817478
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
[TBL] [Abstract][Full Text] [Related]
9. Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.
Heide T; Maurer A; Eipel M; Knoll K; Geelvink M; Veeck J; Knuechel R; van Essen J; Stoehr R; Hartmann A; Altmueller J; Graham TA; Gaisa NT
J Pathol; 2019 Jun; 248(2):230-242. PubMed ID: 30719704
[TBL] [Abstract][Full Text] [Related]
10. Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases.
Sjödahl G; Eriksson P; Lövgren K; Marzouka NA; Bernardo C; Nordentoft I; Dyrskjøt L; Liedberg F; Höglund M
Mod Pathol; 2018 Dec; 31(12):1869-1881. PubMed ID: 29967424
[TBL] [Abstract][Full Text] [Related]
11. CK5/6 and GATA3 Defined Phenotypes of Muscle-Invasive Bladder Cancer: Impact in Adjuvant Chemotherapy and Molecular Subtyping of Negative Cases.
Koll FJ; Schwarz A; Köllermann J; Banek S; Kluth L; Wittler C; Bankov K; Döring C; Becker N; Chun FKH; Wild PJ; Reis H
Front Med (Lausanne); 2022; 9():875142. PubMed ID: 35783619
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathology of the luminal class of urothelial tumors.
Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
[TBL] [Abstract][Full Text] [Related]
14. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
[TBL] [Abstract][Full Text] [Related]
15. Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.
da Costa JB; Gibb EA; Nykopp TK; Mannas M; Wyatt AW; Black PC
Urol Oncol; 2022 Jul; 40(7):287-294. PubMed ID: 30528886
[TBL] [Abstract][Full Text] [Related]
16. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
17. Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer.
Tan TZ; Heong V; Ye J; Lim D; Low J; Choolani M; Scott C; Tan DSP; Huang RY
J Pathol; 2019 Mar; 247(3):305-319. PubMed ID: 30374975
[TBL] [Abstract][Full Text] [Related]
18. Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer.
Rinaldetti S; Worst TS; Rempel E; Kriegmair MC; Hartmann A; Porubsky S; Bolenz C; Erben P
Sci Rep; 2020 Nov; 10(1):20472. PubMed ID: 33235218
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer.
Jackson CL; Chen L; Hardy CS; Ren KY; Visram K; Bratti VF; Johnstone J; Sjödahl G; Siemens DR; Gooding RJ; Berman DM
J Pathol Clin Res; 2022 Mar; 8(2):143-154. PubMed ID: 34697907
[TBL] [Abstract][Full Text] [Related]
20. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Lang H; Béraud C; Cabel L; Fontugne J; Lassalle M; Krucker C; Dufour F; Groeneveld CS; Dixon V; Meng X; Kamoun A; Chapeaublanc E; De Reynies A; Gamé X; Rischmann P; Bieche I; Masliah-Planchon J; Beaurepere R; Allory Y; Lindner V; Misseri Y; Radvanyi F; Lluel P; Bernard-Pierrot I; Massfelder T
Front Oncol; 2022; 12():930731. PubMed ID: 36033544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
